Skip to content
Mainboard DRHP Filed
Claroid Pharmaceuticals Limited logo

Claroid Pharmaceuticals IPO (DRHP filed)

Claroid Pharmaceuticals Limited filed its draft red herring prospectus with SEBI on 6 Oct 2026. Price band, lot size and issue dates are announced only after SEBI observations and the RHP filing.

Last updated

Stage
DRHP Filed
DRHP filed
6 Oct 2026
Days since
12
Issue size
—
Board
Mainboard
Price band
TBA

Claroid Pharmaceuticals IPO status

Claroid Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on . The issue can open only after SEBI issues its observations and the company files the RHP with the price band.

DRHP filed 6 Oct 2026
Days since filing 12
SEBI observation Awaited
Price band TBA
Issue dates TBA

Share reservation by category

Category Shares Details
Qualified Institutions Not More Than 50% of the Net Issue
Retail Investors Not Less Than 35% of the Net Issue
Non-Institutional Not Less Than 15% of the Net Issue

Claroid Pharmaceuticals Limited financials

Between 31 Mar 2025 and 31 Mar 2026, Income rose from ₹100.17 Cr to ₹173.91 Cr, and profit after tax rose from ₹7.22 Cr to ₹22.7 Cr. The PAT margin for 31 Mar 2026 was 13.05%.

Period ended 31 Mar 2026 31 Mar 2025 31 Mar 2024
Assets 117.21 94.34 56.10
Total Income 173.91 100.17 63.61
Profit After Tax 22.70 7.22 4.12
EBITDA 40.94 14.35 11.77
Net Worth 44.38 21.69 14.47
Reserve & Surplus 29.38 20.19 12.97
Total Borrowings 27.46 40.54 29.00

₹ in crore, as stated in the prospectus.

Key performance indicators

KPI Mar 2026 Mar 2025 Mar 2024
ROE % 68.73 39.90 72.53
ROCE % 52.66 21.74 21.07
Debt / Equity 0.62 1.87 2.00
RoNW % 51.16 33.26 28.44
Pat Margin % 13.06 7.20 6.47

Peer comparison

Company Face value P/E EPS (basic) EPS (diluted) RoNW NAV
Claroid Pharmaceuticals Limited 10 — 5.41 5.41 51.16% 10.57
Bafna Pharmaceuticals Ltd 10 99.90 4.69 4.69 15.31% 40.64
Syncom Formulations (India) Ltd 1 21.90 0.81 0.81 20.21% 4.41
Lincoln Pharmaceuticals Ltd 10 12.60 43.88 43.88 11.80% 378.25

From the prospectus. P/E is shown as — when earnings are zero or negative, or not reported for the issuer before listing.

Objectives

The company intends to allocate the net proceeds from the offering to the following objectives.

Sr Objective Est Amt (₹ Cr.)
1 Funding of capital expenditure requirement for setting up of the Proposed Plant 167.97
2 General Corporate purposes —
Total 167.97

About Claroid Pharmaceuticals Limited

Incorporated in August 2018, Claroid Pharmaceuticals Limited is a pharmaceutical formulations manufacturing company engaged in the development and manufacture of generic pharmaceutical products, including tablets and ointments, as well as the encapsulation of pharmaceutical formulations into hard gelatin capsules. The Company primarily caters to semi-regulated international markets, with a particular focus on exports to countries in Africa.

The Company operates a manufacturing facility located at Pirana, Ahmedabad, Gujarat, spread across approximately 12,332 square metres. The facility comprises dedicated production, quality control, warehousing, utilities and other supporting infrastructure required for pharmaceutical manufacturing. It has an effective annual manufacturing capacity of approximately 14,400 lakh tablets, 9,360 lakh capsules and 120 lakh units of ointment. The manufacturing facility has been designed to facilitate efficient material movement and coordination across various stages of the production process.

Since commencing commercial operations, the Company has focused on maintaining product quality, regulatory compliance, product development and expanding its export-oriented business. Its manufacturing facility holds manufacturing licences under the Drugs and Cosmetics Act, State GMP certifications and various regulatory approvals, including WHO-GMP (CDSCO), NAFDAC (Nigeria), TMDA (Tanzania), RFDA (Rwanda), SBDMA (Yemen) and ZFDA (Zanzibar). These approvals support the export of the Company's pharmaceutical products to the respective international markets, subject to applicable regulatory requirements.

The Company follows a diversified product and market strategy, with its generic formulations business supported by product selection, formulation development and regulatory registrations across multiple geographies. Its operations are supported by an experienced management team and a workforce engaged across key functions, including production, packing, quality assurance, quality control, engineering, regulatory affairs, formulation and development, warehousing, finance and administration.

As of August 31, 2026, the Company had a total workforce of 203 employees across its various operational, technical, regulatory and administrative functions.

Promoters

  1. Baiju Bhupendrabhai Desai

  2. Soni Snehalkumar Hasmukhlal

  3. Rushin Baijubhai Desai

  4. Patel Shaileshbhai Arjanbhai

  5. Patel Ghanshyam Arjanbhai

Contact details

Claroid Pharmaceuticals Limited
S.No -217/P Opp Gurukul English School
Kamod-Pirana Road, Pirana
Ahmedabad, Gujarat, 382425

Telephone: +91 80008 17999
Email: cs@claroidpharma.com
Website: https://www.claroidpharma.com/

Claroid Pharmaceuticals IPO FAQs

Has Claroid Pharmaceuticals IPO filed for an IPO?
Claroid Pharmaceuticals Limited filed its draft red herring prospectus (DRHP) with SEBI on 6 Oct 2026.
When will the Claroid Pharmaceuticals IPO open?
Issue dates are announced after SEBI observations and the RHP filing. They are not available yet.
What is the Claroid Pharmaceuticals IPO price band?
The price band is announced a few days before the issue opens. It is not available yet.

Details are from the draft prospectus and can change in the final RHP. This is not investment advice.